Home › Compound Library › Dulaglutide (Trulicity)

Dulaglutide (Trulicity)

Peptideprescriptionsubcutaneous · inferred

Long-acting GLP-1 receptor agonist consisting of two GLP-1 analogs fused to a human IgG4 Fc fragment, giving a ~5-day half-life suitable for once-weekly SC injection. Approved for type 2 diabetes and cardiovascular risk reduction; REWIND established benefit in a broad T2D population. Dosing 0.75-4.5 mg SC weekly.

Projected serum levels — 1.5 mg, weekly

Dulaglutide (Trulicity)
Dulaglutide (Trulicity) modeled serum levels, 1.5 mg weekly over 42 days Population-based pharmacokinetic estimate. Steady state reached after approximately 14 days. 0 0.50 1 1.5 2 Day 0 Day 11 Day 21 Day 32 Day 42 Time on a regular schedule ≈ steady state · day 14
Dulaglutide (Trulicity) modeled serum levels with a loading dose of 2.5 mg, then 1.5 mg weekly The first dose is larger so levels approach steady state faster. 0 0.50 1 1.5 2 Day 0 Day 11 Day 21 Day 32 Day 42 Time on a regular schedule

Maintenance schedule: 1.5 mg weekly (subcutaneous).

Loading schedule: 2.5 mg on day 1, then 1.5 mg weekly — reaching therapeutic levels sooner.

Modeled steady state after ~14 days: peak ≈ 1.1 mg, trough ≈ 0.58 mg body load. Population-based estimate over 42 days for a 1.5 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Peptide
Route modeled
Subcutaneous
Model confidence
inferred
Half-life
5 days
Common dose
1.5 mg
Suggested maximum
4.5 mg/day
Reference dose range
0.75–4.5 mg (single dose)
Suggested cadence
weekly
Validated against
0.75 mg sc — Cmax 0.11 mg/L at 48 h

Documented interactions

  • watch
    Liraglutide (Victoza/Saxenda) + Dulaglutide (Trulicity) Stacked effects

    Dulaglutide (Trulicity) and Liraglutide (Victoza/Saxenda) both push the glp1 receptor in the same direction.

  • watch
    Retatrutide (Reta) + Dulaglutide (Trulicity) Stacked effects

    Dulaglutide (Trulicity) and Retatrutide (Reta) both push the glp1 receptor in the same direction.

  • watch
    Semaglutide (Ozempic/Wegovy) + Dulaglutide (Trulicity) Stacked effects

    Dulaglutide (Trulicity) and Semaglutide (Ozempic/Wegovy) both push the glp1 receptor in the same direction.

  • watch
    Sitagliptin (Januvia) + Dulaglutide (Trulicity) Stacked effects

    Dulaglutide (Trulicity) and Sitagliptin (Januvia) both push the glp1 receptor in the same direction.

  • watch
    Tirzepatide (Mounjaro/Zepbound) + Dulaglutide (Trulicity) Stacked effects

    Dulaglutide (Trulicity) and Tirzepatide (Mounjaro/Zepbound) both push the glp1 receptor in the same direction.

Serum checks 5 modeled interaction pairings for dulaglutide (trulicity) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Gerstein HC et al. · Lancet, 2019 DOI

    REWIND RCT of 9901 T2D patients across the CV risk spectrum showed weekly dulaglutide reduced major adverse CV events by 12% over 5.4 years, notably in a predominantly primary-prevention population.

  2. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1) Wysham C et al. · Diabetes Care, 2014 DOI

    AWARD-1 RCT of 976 T2D patients demonstrated once-weekly dulaglutide was superior to twice-daily exenatide for HbA1c reduction over 26 weeks.

  3. Dulaglutide: a review of its pharmacology and clinical pharmacokinetics Jimenez-Solem E et al. · Expert Opinion on Drug Metabolism & Toxicology, 2015 DOI

    Review characterizing dulaglutide's ~47% absolute bioavailability after SC injection, elimination half-life of ~4.7 days, and degradation via general protein catabolism.

3 published studies referenced in the app, each with a plain-language summary.